



COVID-19 Respiratory Plus Microbiota Panel 384 Well

Product Specification Sheet

RUO Product*

Product Description:

The Respiratory Plus Microbiota Panel is an in-vitro multiplex real-time reverse transcription polymerase chain reaction (rRT-PCR) assay for the qualitative identification of nucleic acids from organisms frequently found in the respiratory tract. This method is highly accurate, analytically sensitive, and is used to identify organisms by amplifying and detecting genetic material of pathogens in samples. The panel will aid in the research of causative agents of respiratory tract infections and their prevalence.

The target organisms included in the panel are as follows: Adenovirus, Bocavirus, Coronavirus (229E, HKU1, NL63, OC43), Epstein-Barr virus, Enterovirus, Human Metapneumovirus (HMPV A&B), Influenza A&B, Parainfluenza (types 1-4), Rhinovirus, RSV, SARS-CoV-2 (COVID-19), Acinetobacter baumannii, Bordetella pertussis, Chlamydia pneumoniae, Enterobacter cloacae, Haemophilus influenzae, Klebsiella aerogenes, Klebsiella pneumoniae, Legionella pneumophila, Moraxella catarrhalis, Mycoplasma pneumoniae, Proteus mirabilis, Pseudomonas aeruginosa, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus pneumoniae, and Streptococcus pyogenes (Group A Strep). The panel also detects mecA, which is a gene responsible for Methicillin/ Oxacillin resistance.

Product Information	
COVID-19 Respiratory Plus Microbiota Panel Plate (384 well Plate)	
Part Number	P-CRP384-001-A P-CRP384-002-A
Number of Reactions	12
Storage Temperature	-25°C to -15°C

Product Specifications	
QC Test	qPCR Cycle Threshold Percent CV
Specification	≤ 2.5

QC Results	
Positive	meets specification
Negative	meets specification
Targets	meets specification

Disclaimer - Use of PCR and Patent

This product is for basic PCR and is outside of any valid US patents assigned to Hoffman La-Roche.

* Limitations of Use

For Research Use Only. Not for use in diagnostic procedures.

Product Guarantee

This kit is proven in PCR and generates reliable, repeatable and high-performance results. Please contact Molecular Designs for technical assistance. If not completely satisfied, our team will help you identify and address the issue and replace the assays as needed.

Jaspreet Seth

Vice President, Quality
Molecular Designs, LLC

Usage Information



▶ Reagent Storage and Use Guidelines

1. Store all reagents at -25°C to -15°C.
2. Do not freeze-thaw plates more than 3 times.

▶ The Following is Included in the Kit:

1. 384-well PCR plate pre-loaded with the COVID-19 Respiratory Plus Microbiota assays and positive and negative controls

▶ The Following is Supplied by the User: Materials

1. Extracted Sample(s)
2. qPCR optical film
3. Sealer for optical film

▶ Equipment

1. Manual defrost -20°C freezer
2. Laminar Flow or PCR Dead Air Box for general plate setup. Do not use Laminar Flow for infectious samples
3. Pipette and appropriate filtered pipette tips
4. Plate Vortex [recommend Vortex Genie 2 (Model G560) with the 3-inch platform and rubber cover]
5. Plate centrifuge

▶ Instrumentation

CFX384 Touch Real-Time PCR Detection System (or equivalent)

▶ General Guidelines and Safety Precautions

1. As with any test procedure, good laboratory practice is essential to the proper performance of this assay. Due to the high sensitivity of this test, care should be taken to keep reagents and amplification mixtures free of contamination.
 - a) Do not pipette by mouth.
 - b) Do not eat, drink, or smoke in designated work areas.
 - c) Wear laboratory gloves, laboratory coats, and eye protection when handling samples and reagents. Gloves must be changed between handling samples to prevent contamination. Avoid contaminating gloves when handling samples and controls.
 - d) Wash hands thoroughly after handling samples and kit reagents, and after removing the gloves.
 - e) Thoroughly clean and disinfect all laboratory work surfaces.

NOTE: Do not use sodium hypochlorite solution (bleach) to clean up a spill or to disinfect a plate before disposal as it can react with the common extraction reagents and generate toxic byproducts. If spills occur, follow internal procedures to immediately clean and decontaminate the surface of instrument.
2. A laminar flow or PCR Dear Air Box is recommended to reduce contamination probability.
3. The use of filtered, sterile and nuclease-free pipette tips is recommended.
4. False positive results may occur if carryover of samples is not adequately controlled during sample handling and processing.



Usage Information



▶ Reaction Plate Setup

1. Remove a reaction plate from the -20°C manual defrost freezer.
2. Use the plate within 1 hour of thawing, keep sealed and store refrigerated at 4°C if not using immediately.
3. Spin down the plate for 30 seconds in a plate centrifuge.
4. Carefully remove the foil seal from the plate.
5. Add 4.0 µL of the sample being tested to each of the target wells.
NOTE: 384-well plates have 16 rows (labeled A:P) and 24 columns (labeled 1:24). When plating a sample, alternate rows are pipetted to accommodate the use of a multichannel pipette. Refer page 5 of this document for detailed well/panel layout.
6. Do not add any additional liquid to the RT Control, Positive Control and Negative Control wells. All components have been added to these wells.
7. Seal the PCR plate using optical qPCR film.
8. Vortex the plate, at least 5 seconds per plate quadrant.
9. Spin down the plate in a plate centrifuge.

▶ Procedural Notes

1. Do not reuse consumables. They are for one-time use only.
2. Always use caution when transferring specimens from a primary collection tube to a secondary tube.
3. Use pipettes with aerosol-barrier or positive-displacement tips to handle specimens.
4. Always use a new pipette tip for each specimen.
5. For testing of previously frozen sample, ensure samples are equilibrated to room temperature and well mixed prior to use.

▶ Target Layout per panel (384 well plate, 12 panels per plate) See Page 5-6 for complete layout of a 384-well plate

Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii
HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P.aeruginosa (VIC)
HMPV B	HCoV 229E	M. catarrhalis	E. cloacae
Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)
Rhinovirus	PIV 3	RP (FAM)	P. mirabilis
Adenovirus	PIV 2/ PIV 4 (CFO)	RT Control	S. epidermidis
Bocavirus/ EBV (VIC)	S. pneumoniae	Positive Control	L. pneumophila
SARS-CoV-2	S. pyogenes/ M. pneumoniae (VIC)	Negative Control	mecA

If not noted, the fluorophore is FAM and the second channel is noted in parentheses signifying a secondary target in the primer and probe mixture which will be detected on the qPCR instrument. CFO is equivalent to CAL Fluor Orange 560.



Usage Information



▶ Real-Time PCR Detection System qPCR Run Setup

1. Open the specified run template and fill in the sample name fields with unique sample IDs corresponding to the samples being processed.
2. **NOTE:** This step can also be done prior to reaction plate setup if sample IDs have already been specified.
3. Place the reaction plate into the instrument in the appropriate orientation (A1 in the upper left corner), close the instrument lid and initiate the run.

▶ Thermocycling Protocol

1. Reverse Transcription
 - a) 5 minutes at 50°C
2. Denaturation
 - a) 3 minutes at 95°C
3. Annealing and Extension
 - a) 5 seconds at 95°C
 - b) 30 seconds at 60°C, with fluorescence acquisition during this step

▶ Amplification Interpretation and Troubleshooting

1. The laboratory should establish cycle threshold (CT) cutoffs as appropriate for their sample workflow and procedures. It is recommended that CT cutoffs are determined during the validation of the test.
2. The laboratory should evaluate the curve shape when considering whether a sample with a given CT should be considered positive:
 - a) Plate sealing issues can lead to jagged curve shapes or rising/decreasing baselines that lead to inaccurate data (erroneous CT value).
 - b) Inappropriate mixing or centrifuging can lead to inaccurate data.
3. If user suspects contamination, it is recommended to clean and disinfect the laboratory area and re-test to ensure proper results.
4. Any failure of the positive or negative control should require a repeat run. If the control failure continues, it is recommended to have the qPCR instrument and the sample extraction workflow evaluated to ensure they are functioning properly.



Respiratory Plus Microbiota Plate Map

384-well – Columns 1-12



	Patient 1 (White) and 2 (Grey)				Patient 3 (Dark Grey) and 4 (Black)				Patient 5 (White) and 6 (Grey)			
	1	2	3	4	5	6	7	8	9	10	11	12
A	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii
B	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii
C	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)
D	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)
E	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae
F	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae
G	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)
H	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)
I	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis
J	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis
K	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis
L	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis
M	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila
N	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila
O	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA
P	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA



Respiratory Plus Microbiota Plate Map

384-well – Columns 13-24



	Patient 7 (Dark Grey) and 8 (Black)				Patient 9 (White) and 10 (Grey)				Patient 11 (Dark Grey) and 12 (Black)			
	13	14	15	16	17	18	19	20	21	22	23	24
A	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii
B	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii	Influenza A/ Influenza B (CFO)	RSV/ HCoV HKU1 (CFO)	B. pertussis	A. baumannii
C	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)
D	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)	HMPV A	HCoV OC43/ HCoV NL63 (CFO)	H. influenzae	K. aerogenes/ P. aeruginosa (VIC)
E	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae
F	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae	HMPV B	HCoV 229E	M. catarrhalis	E. cloacae
G	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)
H	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)	Enterovirus	PIV 1	S. aureus/ C. pneumoniae (VIC)	K. pneumoniae (CFO)
I	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis
J	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis	Rhinovirus	PIV 3	RP	P. mirabilis
K	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis
L	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis	Adenovirus	PIV 2/ PIV 4 (CFO)		S. epidermidis
M	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila
N	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae		L. pneumophila	Bocavirus/ EBV (VIC)	S. pneumoniae	RTC	L. pneumophila
O	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)	PC	mecA
P	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)		mecA	SARS-CoV-2	S. pyogenes / M. pneumoniae (VIC)	NC	mecA

